• Medientyp: E-Artikel
  • Titel: Pax8, Napsin A, and CD10 as Immunohistochemical Markers of Canine Renal Cell Carcinoma
  • Beteiligte: Peat, Tyler J.; Edmondson, Elijah F.; Miller, Margaret A.; DuSold, Dee M.; Ramos-Vara, José A.
  • Erschienen: SAGE Publications, 2017
  • Erschienen in: Veterinary Pathology
  • Sprache: Englisch
  • DOI: 10.1177/0300985817698211
  • ISSN: 0300-9858; 1544-2217
  • Schlagwörter: General Veterinary
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Pax8, napsin A, and CD10 are useful immunohistochemical markers of human renal cell carcinoma (RCC); however, their diagnostic utility in canine RCC is unclear. Forty formalin-fixed paraffin-embedded renal cell carcinomas from dogs (15 papillary, 12 solid, and 13 tubular) and 10 metastases were evaluated for expression of Pax8, napsin A, and CD10. Thirty-nine (98%), 24 (60%), and 19 (50%) tumors expressed Pax8 (nuclear labeling), napsin A (cytoplasmic labeling), and CD10 (cytoplasmic and membranous labeling), respectively. Pax8 was expressed in 92% of solid, 100% of papillary, and 100% of tubular tumors. Napsin A was expressed in 58% of solid, 60% of papillary, and 62% of tubular RCC. CD10 was expressed in 33% of solid, 47% of papillary, and 62% of tubular RCC. Pax8 was expressed in 80% of the metastatic tumors, napsin A in 60%, and CD10 in 50%. Additionally, Pax8 immunoreactivity was stronger overall than that of napsin A or CD10. In summary, Pax8 is a more sensitive marker than napsin A or CD10 for primary and metastatic canine RCC; its nuclear and more intense reactivity also makes it easier to interpret. Tubular and papillary RCCs were more likely than solid RCC to express all 3 markers. These findings highlight the utility of Pax8 as an immunohistochemical marker in diagnosing all major subtypes of canine primary and metastatic renal cell carcinoma.</jats:p>
  • Zugangsstatus: Freier Zugang